SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/20/2018 9:51:38 AM - Followers: 136 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
SureTrader
RXII
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4643   RXII 2.80 OVERSOLD last IPO 3.15, I am Blutribe 04/20/18 09:51:38 AM
#4642   How many people fell for the halt to The Other Guy 04/04/18 08:23:19 PM
#4641   * * $RXII Video Chart 04-04-18 * * ClayTrader 04/04/18 05:24:02 PM
#4640   nice SM! $RXII +30% with multiple presentations coming $treet $inatra 04/04/18 10:29:14 AM
#4639   https://finance.yahoo.com/news/rxi-pharmaceuticals-present-clinical-cosmetic-110 [SMART MONEY] 04/04/18 10:02:12 AM
#4638   weeeeeeeeeeeeee crowin 04/04/18 09:59:59 AM
#4637   yep I hope people read this stuff and Inoviorulez 03/28/18 06:07:30 PM
#4636   I AGREE 1000% And would avoid RXII at NGIN 03/28/18 09:21:58 AM
#4635   Yep now they said the data wasn't available Inoviorulez 03/27/18 11:29:15 AM
#4634   The old dangling of carrots 12-18 months out. The Other Guy 03/27/18 11:06:38 AM
#4633   We've ALL BEEN DUPED...AGAIN... Geert is GREAT at NGIN 03/26/18 08:00:41 PM
#4632   yes, can't say i blame them. The most Inoviorulez 03/26/18 05:26:59 PM
#4631   Will Geert release news Monday? BioPharma 03/23/18 02:43:17 PM
#4630   Total institions holding only 2%? Most institutions sold BioPharma 03/21/18 05:36:15 PM
#4629   Year end financials conference on Monday will Geert BioPharma 03/21/18 05:26:41 PM
#4628   close below its MA200 today https://stockcharts.com/c-sc/sc?s=RXII&p=D&b=4& $treet $inatra 03/15/18 04:08:35 PM
#4627   Needs to hold the pre-RS price today. The The Other Guy 03/15/18 10:52:22 AM
#4626   RXii Low Floater Play !!! zino 03/15/18 10:27:27 AM
#4625   The day after is always a disaster. The Other Guy 03/14/18 07:57:41 PM
#4624   You again? Everybody sell now!!! HoaxDevil 03/14/18 06:04:25 PM
#4623   * * $RXII Video Chart 03-14-18 * * ClayTrader 03/14/18 05:15:00 PM
#4622   this could run to new 3Y highs greenvestor2000 03/14/18 03:51:10 PM
#4621   just saw several +5% bounds - looks pretty greenvestor2000 03/14/18 03:49:12 PM
#4620   Yeah. I’m nervous as hell that could be The Other Guy 03/14/18 03:32:46 PM
#4619   TOG, I would be wary about the recent InternetForumUser 03/14/18 02:12:55 PM
#4618   Quite the volatility. LPC dancing with this stock? The Other Guy 03/14/18 01:02:29 PM
#4617   first for dilution for sure, but yah after Inoviorulez 03/13/18 09:29:20 PM
#4616   sec filing for new dillution or for another inrags86 03/13/18 01:24:39 PM
#4615   So when does the new sec filing come The Other Guy 03/13/18 01:22:06 PM
#4614   Thanks clay! Always look forward to a The Other Guy 03/12/18 08:03:18 PM
#4613   * * $RXII Video Chart 03-09-18 * * ClayTrader 03/09/18 05:09:54 PM
#4612   It’s very similar to what was done last The Other Guy 03/09/18 04:24:37 PM
#4611   How does the LPC dilution work? Dilution means sabaidii2 03/09/18 02:55:31 PM
#4610   This run up is definitely product of LPC. Inoviorulez 03/09/18 02:44:47 PM
#4609   I was asking what you meant by “LPC” The Other Guy 03/09/18 12:36:55 PM
#4608   "Oh, you mean Lincoln Park Capital. Was wondering sabaidii2 03/09/18 11:56:06 AM
#4607   Oh, you mean Lincoln Park Capital. Was wondering The Other Guy 03/09/18 10:43:54 AM
#4606   "LPC?" I assume you're referring to the share sabaidii2 03/09/18 10:33:38 AM
#4605   Obviously “better” results than what has been published The Other Guy 03/09/18 09:10:08 AM
#4604   That's true, they could have done so much Inoviorulez 03/08/18 04:55:26 PM
#4603   Define "positive results". RXI's definition is BS. sabaidii2 03/08/18 12:22:29 PM
#4602   Curious if you think even positive results would The Other Guy 03/07/18 04:10:48 PM
#4601   Retinal scar RXI-109 P1/2 results will be released BioPharma 03/06/18 01:36:55 PM
#4600   The stock price keeps dropping, it does not BioPharma 02/28/18 07:31:06 PM
#4599   Buyout? would be GREAT...IF this company was actually NGIN 02/27/18 08:20:08 PM
#4598   Buyout? sabaidii2 02/26/18 06:00:38 PM
#4597   Buyout? BioPharma 02/25/18 06:45:03 PM
#4596   Geert, How about having a company that drives BioPharma 01/26/18 05:05:54 PM
#4595   Absolutely CORRECT in my opinion as a long NGIN 01/23/18 01:52:43 PM
#4594   Jan 8, 2018 Bio Showcase Conference presentation: sabaidii2 01/20/18 06:37:34 PM
PostSubject